DNA methylation and urological cancer, a step towards personalized medicine: current and future prospects.
Identifiers
Permanent link (URI): http://hdl.handle.net/10017/58989DOI: 10.1007/s40291-016-0231-2
ISSN: 1177-1062
Date
2016-08-09Funders
Ministerio de Sanidad
Bibliographic citation
Molecular Diagnosis and Therapy, 2016
Project
info:eu-repo/grantAgreement/MSCBS/Fondo de Investigaciones Sanitarias/FIS11%2F608/ES//
Document type
info:eu-repo/semantics/article
Version
info:eu-repo/semantics/publishedVersion
Rights
© Springer International Publishing Switzerland 2016
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Access rights
info:eu-repo/semantics/openAccess
Abstract
Urologic malignancies are some of the com- monest tumors often curable when diagnosed at early stage. However, accurate diagnostic markers and faithful pre- dictors of prognosis are needed to avoid over-diagnosis leading to overtreatment. Many promising exploratory studies have identified epigenetic markers in urinary malignancies based on DNA methylation, histone modifi- cation and non-coding ribonucleic acid (ncRNA) expres- sion that epigenetically regulate gene expression. We review and discuss the current state of development and the future potential of epigenetic biomarkers for more accurate and less invasive detection of urological cancer, tumor recurrence and progression of disease serving to establish diagnosis and monitor treatment efficacies. The specific clinical implications of such methylation tests on thera- peutic decisions and patient outcome and current limita- tions are also discussed.
Files in this item
Files | Size | Format |
|
---|---|---|---|
DNA_methilatin_MDT_2016.pdf | 473.0Kb |
|
Files | Size | Format |
|
---|---|---|---|
DNA_methilatin_MDT_2016.pdf | 473.0Kb |
|
Collections
- BIOQBM - Artículos [137]